Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & Korsinsky

Liquidia shareholders took a roughly 57% loss after a court found that Yutrepia infringed two valid United Therapeutics patent claims. The investigation concerns whether investors had an accurate picture of that litigation risk before the losses occurred.

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- For Liquidia Corporation (NASDAQ: LQDA) shareholders, a court finding that Yutrepia infringed two valid claims of United Therapeutics' '327 patent produced a roughly 57% closing loss. If you held LQDA when the ruling hit, or sold into the decline, you may have legal rights. Investors who lost money on Liquidia are encouraged to submit their loss details for review today. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

Yutrepia is the product at the center of the ruling. In its Form 10-Q filed August 12, 2026, Liquidia reported $300.3 million in Yutrepia sales for the first six months of 2026. The same filing listed approximately $69.1 million in non-cancelable manufacturing and supply commitments. United Therapeutics has sought an injunction.

CEO Roger Jeffs said Liquidia disagrees with the decision and will pursue appellate options. Levi & Korsinsky is investigating whether Liquidia investors were given an accurate picture of the patent litigation's status and potential consequences before these losses occurred.

If you bought Liquidia shares and are now sitting on a loss, find out whether you may be eligible to recover or call (212) 363-7500.

Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.

Frequently Asked Questions About the LQDA Investigation

Q: How much did LQDA stock drop?A: Shares fell approximately 57% after a court found that Yutrepia infringed two valid claims of United Therapeutics' '327 patent. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether Liquidia Corporation made materially false or misleading statements regarding the status and potential consequences of United Therapeutics' patent litigation over Yutrepia. When the court's finding that Yutrepia infringed two valid claims of the '327 patent became known, the stock price declined sharply.

Q: Who is eligible to participate in the LQDA investigation?A: Investors who purchased LQDA stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: What do LQDA investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my LQDA shares -- can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought LQDA and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Q: Do I need to go to court or give testimony?A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

SOURCE Levi & Korsinsky, LLP